Abstract
CNs are often involved in a wide range of acquired and hereditary muscle disorders. Involvement of CNs in myopathies concern either single nerves or multiple nerves affected at the same time. CN involvement in myopathies ranges from ophthalmoplegia and/or ptosis, to facial weakness and bulbar muscle weakness with dysphagia, dysarthria, and/or dyspnea. Several of the underlying muscle diseases and their differentials are treatable; therefore, timely recognition is important.
Author of this chapter: Kristl G. Claeys.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
McClelland C, Manousakis G, Lee MS. Progressive external ophthalmoplegia. Curr Neurol Neurosci Rep. 2016;16:53.
Tsang SH, Aycinena ARP, Sharma T. Mitochondrial disorder: Kearns-Sayre syndrome. Adv Exp Med Biol. 2018;1085:161–2.
Moraes CT, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns Sayre syndrome. N Engl J Med. 1989;320:1293–9.
Milone M, Wong LJ. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110:35–41.
Tasfaout H, Cowling BS, Laporte J. Centronuclear myopathies under attack: a plethora of therapeutic targets. J Neuromuscul Dis. 2018;5:387–406.
Claeys KG. Congenital myopathies: an update. Dev Med Child Neurol. 2020;62:297–302.
Johnson NE. Myotonic muscular dystrophies. Continuum (Minneap Minn). 2019;25:1682–95.
Mackenzie SJ, Hamel J, Thornton CA. Benefits of aerobic exercise in myotonic dystrophy type 1. J Clin Invest. 2022;132:e160229.
Izzo M, Battistini J, Provenzano C, Martelli F, Cardinali B, Falcone G. Molecular therapies for myotonic dystrophy type 1: from small drugs to gene editing. Int J Mol Sci. 2022;23:4622–47.
Sacconi S, Briand-Suleau A, Gros M, Baudoin C, Lemmers RJLF, Rondeau S, et al. FSHD1 and FSHD2 form a disease continuum. Neurology. 2019;92:e2273–85.
Wang LH, Tawil R. Current therapeutic approaches in FSHD. J Neuromuscul Dis. 2021;8:441–51.
Mirabella M, Silvestri G, de Rosa G, Di Giovanni S, Di Muzio A, Uncini A, et al. GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy. Neurology. 2000;54:608–14.
Brais B, Bouchard JP, Xie YG, Rochefort DL, Chrétien N, Tomé FM, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 1998;18:164–7.
Yamashita S. Recent progress in oculopharyngeal muscular dystrophy. J Clin Med. 2021;10:1375–85.
Machado PM, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis: new insights and potential therapy. Curr Opin Neurol. 2014;27:591–8.
Herbert MK, Pruijn GJ. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility. Curr Opin Rheumatol. 2015;27:595–600.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Claeys, K.G. (2023). Cranial Nerves and Myopathies. In: The Cranial Nerves in Neurology. Springer, Cham. https://doi.org/10.1007/978-3-031-43081-7_24
Download citation
DOI: https://doi.org/10.1007/978-3-031-43081-7_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-43080-0
Online ISBN: 978-3-031-43081-7
eBook Packages: MedicineMedicine (R0)